FDA Approves First Generic Liraglutide Once-Daily Injection
By Lori Solomon HealthDay Reporter
THURSDAY, Dec. 26, 2024 -- The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.
The approval of the once-daily injection (18 mg/3 mL), as an adjunct to diet and exercise, is intended to help with drug shortages and improve patient access.
The generic liraglutide includes a Boxed Warning to advise health care professionals and patients about the increased risk for thyroid C-cell tumors. Additional warnings include pancreatitis, liraglutide pen sharing, hypoglycemia when used in conjunction with certain other drugs known to cause hypoglycemia like insulin and sulfonylurea, renal impairment or kidney failure, hypersensitivity, and acute gallbladder disease. Clinical trials revealed the most common side effects were nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation.
"The FDA supports development of complex generic drugs, such as GLP-1s, by funding research and informing industry through guidance as part of our ongoing efforts to increase access to needed medications," Iilun Murphy, M.D., director of the FDA Office of Generic Drugs, said in a statement. "Today's approval underscores the FDA's continued commitment to advancing patient access to safe, effective, and high-quality generic drug products."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Muscle Ultrasound Can Detect Insulin Resistance
MONDAY, June 30, 2025 -- Muscle ultrasound can detect insulin resistance and lower muscle mass, according to a study published online June 12 in the Journal of Ultrasound...
Disparities Seen in Continuous Glucose Monitor Rx by Language Preference
FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...
ADA: Insulin Efsitora Noninferior to Glargine for Reducing HbA1c in Adults With Type 2 Diabetes
FRIDAY, June 27, 2025 -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.